683 Capital Management LLC Invests $878,000 in Armata Pharmaceuticals, Inc. $ARMP

683 Capital Management LLC acquired a new position in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 139,860 shares of the company’s stock, valued at approximately $878,000. 683 Capital Management LLC owned approximately 0.38% of Armata Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in Armata Pharmaceuticals during the 4th quarter worth about $108,000. OMERS ADMINISTRATION Corp acquired a new stake in Armata Pharmaceuticals during the 4th quarter worth about $177,000. SeaCrest Wealth Management LLC lifted its position in Armata Pharmaceuticals by 17.3% during the 4th quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock worth $274,000 after acquiring an additional 6,034 shares during the period. Goldman Sachs Group Inc. acquired a new stake in Armata Pharmaceuticals during the 4th quarter worth about $284,000. Finally, State Street Corp lifted its position in Armata Pharmaceuticals by 26.1% during the 4th quarter. State Street Corp now owns 50,800 shares of the company’s stock worth $319,000 after acquiring an additional 10,500 shares during the period. Institutional investors and hedge funds own 3.57% of the company’s stock.

Armata Pharmaceuticals Trading Up 4.0%

NYSEAMERICAN:ARMP opened at $7.06 on Thursday. Armata Pharmaceuticals, Inc. has a 12 month low of $1.75 and a 12 month high of $16.34. The stock has a 50 day moving average of $9.43 and a two-hundred day moving average of $8.40. The firm has a market cap of $259.17 million, a P/E ratio of -0.91 and a beta of 1.21.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($3.16) EPS for the quarter, missing the consensus estimate of ($0.38) by ($2.78). The business had revenue of $0.79 million during the quarter, compared to the consensus estimate of $0.74 million. On average, research analysts forecast that Armata Pharmaceuticals, Inc. will post -1.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ARMP. HC Wainwright lifted their price target on Armata Pharmaceuticals from $9.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. Zacks Research raised Armata Pharmaceuticals to a “hold” rating in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $15.00.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.